Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study).

Yoshihiko Tomita Go Kimura Satoshi Fukasawa Kazuyuki Numakura Yutaka Sugiyama Kazutoshi Yamana Sei Naito Koki Kabu Mototsugu OyaMototsugu Oya

Published in: Japanese journal of clinical oncology (2021)

TTs have favorable antitumor activity in patients with mRCC after ICI, possibly via changing the mechanism of action. Safety signals of TTs after ICI were similar to previous reports. These results indicate that sequential TTs after ICI may contribute for long survival benefit.

Keyphrases

metastatic renal cell carcinoma
dna damage
cell cycle
oxidative stress
single molecule
cell proliferation
cell therapy
electronic health record
replacement therapy
drug induced